Haemophilus Influenzae Type B and Hib Vaccine
On this page
Direct answer
Haemophilus influenzae type b is an encapsulated gram-negative coccobacillus whose polysaccharide capsule makes it a major cause of invasive disease in children under five. Meningitis, epiglottitis and pneumonia are its classic presentations. The Hib conjugate vaccine prevents them by linking that capsule to a protein carrier, so infants can respond to it.
What you must remember
- Organism: a capsulated gram-negative coccobacillus; the type b capsule, polyribosylribitol phosphate (PRP), is the virulent form.
- Meningitis: the commonest invasive form in children under five, with hearing loss, hydrocephalus and subdural effusion among its sequelae.
- Epiglottitis: rapid fever, drooling, stridor and tripoding, typically in children aged about two to six years, with a thumb sign on lateral neck X-ray.
- Airway rule: never examine the throat of a suspected epiglottitis child with a tongue depressor; the airway is secured in a controlled setting.
- Other focal infections: septic arthritis, osteomyelitis, cellulitis and pneumonia, all of which are prevented by the vaccine.
- Household contacts: rifampicin chemoprophylaxis is offered to unvaccinated or incompletely vaccinated contacts after an index case, per current guidance.
- Schedule: the pentavalent vaccine (DTwP-HepB-Hib) is given at 6, 10 and 14 weeks, as a three-dose primary series under the Universal Immunisation Programme; a booster in the second year is an IAP recommendation rather than a UIP dose.
How the conjugate vaccine changes the immune response
Plain polysaccharide fails in infants because the immature immune system does not respond to it. Conjugation solves this by attaching the capsule to a carrier protein. The steps below show why the design works.
- Polysaccharide alone: PRP is a T-cell-independent antigen, so infants under two years mount little antibody and no lasting memory.
- Conjugation: PRP is covalently bound to a protein carrier, such as tetanus toxoid or CRM197, a non-toxic diphtheria toxin variant.
- T-cell help: helper T cells recognise peptides from the carrier, switching the B-cell response to a T-cell-dependent one.
- Memory: the response produces class-switched, high-affinity antibody and immunological memory, so later doses boost protection.
- Schedule: the primary series is given with the pentavalent vaccine, as three doses at 6, 10 and 14 weeks under the Universal Immunisation Programme, and the IAP schedule adds a booster at 15 to 18 months.
- Limits: the vaccine targets type b only and does not protect against non-typeable Haemophilus influenzae or other serotypes.
Where the exam tries to catch you
Vaccine questions reward the reason behind the design. Watch for these traps.
- Trap: Using plain polysaccharide Hib vaccine for infants because it seems simpler. Correct: Infants need the conjugate form, since polysaccharide alone gives a poor, short-lived response before two years.
- Trap: Believing Hib vaccine prevents all Haemophilus infections. Correct: It targets type b only; non-typeable strains cause otitis media and sinusitis and are not covered.
- Trap: Examining a child with suspected epiglottitis with a throat swab or tongue depressor. Correct: Keep the child calm, avoid throat probes and arrange urgent airway support, since complete obstruction can occur.
Frequently asked questions
Which investigation confirms Haemophilus influenzae type b meningitis?
Culture of cerebrospinal fluid or blood is the confirmatory test for Haemophilus influenzae type b meningitis. A CSF Gram stain may show gram-negative coccobacilli, and antigen or molecular tests can help when the child has already received antibiotics.
Why does the conjugate Hib vaccine work in infants when the polysaccharide alone does not?
The conjugate Hib vaccine links the PRP capsule to a protein carrier, which engages T-cell help in infants under two years. Polysaccharide alone gives a T-independent response that is weak and short-lived in this age group, so the conjugate form is used in routine immunisation.
What is given to household contacts after a case of Hib disease?
Rifampicin is the standard chemoprophylaxis for household contacts of an index case of Hib disease, offered to contacts who are unvaccinated or incompletely vaccinated. Eligibility and dosing follow the current national or paediatric infectious disease guidance.
Does the Hib vaccine protect against pneumococcal or meningococcal meningitis?
No. The Hib vaccine covers only Haemophilus influenzae type b and does not protect against Streptococcus pneumoniae or Neisseria meningitidis. Those organisms need their own vaccines, which are scheduled separately from the Hib vaccine.